Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMARTEST: Surgery for Mesothelioma After Radiation Therapy Using Exquisite Systemic Therapy
NCT05380713Phase 2Completed
- Sponsor
- University Health Network
- Start
- May 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in malignant mesothelioma (2 arms), sponsored by University Health Network. Primary endpoint: CD8 Tumor-Infiltrating Lymphocytes density per Gross Tumor Volume up to 5 years. Started May 2022; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT05380713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380713.